Free Trial

Tectonic Therapeutic (NASDAQ:TECX) Coverage Initiated at Lifesci Capital

Tectonic Therapeutic logo with Medical background

Lifesci Capital assumed coverage on shares of Tectonic Therapeutic (NASDAQ:TECX - Free Report) in a report published on Friday morning,Benzinga reports. The brokerage issued an outperform rating and a $87.00 price target on the stock.

A number of other research analysts have also issued reports on TECX. Wells Fargo & Company lowered their target price on Tectonic Therapeutic from $112.00 to $101.00 and set an "overweight" rating on the stock in a report on Friday, March 21st. Mizuho lifted their price target on Tectonic Therapeutic from $51.00 to $85.00 and gave the stock an "outperform" rating in a research note on Thursday, May 15th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $80.50.

View Our Latest Stock Report on Tectonic Therapeutic

Tectonic Therapeutic Price Performance

Shares of TECX traded up $1.42 during trading hours on Friday, reaching $24.48. 193,131 shares of the company's stock traded hands, compared to its average volume of 173,383. The firm has a market capitalization of $457.12 million, a price-to-earnings ratio of -4.16 and a beta of 3.25. Tectonic Therapeutic has a twelve month low of $13.70 and a twelve month high of $61.07. The business's fifty day simple moving average is $19.84 and its two-hundred day simple moving average is $31.36.

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.17. On average, equities research analysts expect that Tectonic Therapeutic will post -8.31 EPS for the current year.

Insiders Place Their Bets

In other Tectonic Therapeutic news, Director Timothy A. Springer acquired 3,718 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was purchased at an average cost of $14.76 per share, for a total transaction of $54,877.68. Following the transaction, the director now owns 4,317,276 shares of the company's stock, valued at $63,722,993.76. The trade was a 0.09% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders acquired 100,696 shares of company stock worth $1,705,714. 38.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tectonic Therapeutic

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in shares of Tectonic Therapeutic by 5,554.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,244 shares of the company's stock valued at $57,000 after buying an additional 1,222 shares during the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of Tectonic Therapeutic during the 4th quarter valued at about $71,000. American Century Companies Inc. acquired a new stake in shares of Tectonic Therapeutic during the 1st quarter valued at about $214,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Tectonic Therapeutic during the 4th quarter valued at about $218,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Tectonic Therapeutic during the 4th quarter valued at about $228,000. 62.63% of the stock is currently owned by institutional investors and hedge funds.

Tectonic Therapeutic Company Profile

(Get Free Report)

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Further Reading

Analyst Recommendations for Tectonic Therapeutic (NASDAQ:TECX)

Should You Invest $1,000 in Tectonic Therapeutic Right Now?

Before you consider Tectonic Therapeutic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tectonic Therapeutic wasn't on the list.

While Tectonic Therapeutic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA: Another 200% Growth Ahead? (PLUS 2 Companies Riding Along)
3 Rising Stocks You’ll Want on Your Watchlist
Trillions in Defense Spending—3 Disruptive Stocks Set to Double

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines